

#### Prevention and Health Promotion Administration Center for Cancer Prevention and Control Cigarette Restitution Fund Program

June 2013



# Serrated Polyps of the Colorectum

W. Sandy Twaddell, MD Department of Pathology University of Maryland

6/17/2013

No disclosures.

#### Overview

- Polyp Types
- Clinical Features of Serrated Polyps
- Molecular Features of Serrated Polyps
- Problems with Serrated Polyps
- Follow-Up of Serrated Polyps

### Colon Polyp Screening

Cancer detection / prevention

#### Colon Polyp Screening

- Cancer detection / prevention
- Removal of precursor lesions (polyps)
- Pathologic identification of polyps
  - Allows risk stratification/appropriate follow-up

#### Polyps

Masses of tissue projecting from the normal surface

- Mesenchymal polyps (lipomas, smooth muscle tumors, etc.)
- Lymphoid tissue
- Pseudopolyps
- Epithelial Polyps- overgrowth of epithelium

#### Normal Colon: Histology


- Straight, narrow crypts
- Small nuclei, at base of cell
- 'Moderate' amount of mucin

### Normal



#### Epithelial Polyps: Histologic Findings

- Bigger nuclei, 'picket fence' or 'cigarshaped'
- Decreased mucin
  or
- Larger crypts with epithelial overgrowth extending into lumen → star-shaped or serrated lumens
- Increased mucin
- Small nuclei





#### Polyp Types: Then

- Adenomatous: less mucin, big nuclei
  - Tubular adenoma
  - Villous adenoma


Hyperplastic Polyp:

increased growth, mucin; stellate/serrated lumens

#### Serrated Polyps

 Traditionally all serrated polyps were defined as hyperplastic polyps, dismissed as benign

 Increasing recognition of some polyps with 'serrated' look, with associated adenomatous features, that were associated with malignancy



#### Polyp Types: Then

- Adenomatous: less mucin, big nuclei
  - Tubular adenoma
  - Villous adenoma

Serrated adenoma less mucin, big nuclei; serrated

- Hyperplastic Polyp
  - increased growth, mucin; stellate/serrated lumens

#### Sessile Serrated Polyps

- Little change in nomenclature / categorization for ~ 10 years
- Starting around 2000, rapidly increasing interest in subtype of serrated polyps
  - Superficially resemble hyperplastic polyps (mucinrich, without 'adenomatous' features) but otherwise atypical for hyperplastic polyps (size, location, etc).
  - Many different names applied to these:
  - hyperplastic polyposis
  - giant hyperplastic polyp
  - giant hyperplastic polyposis
  - large hyperplastic polyps

- hyperplastic-adenomatous polyposis syndrome
- mixed epithelial polyp
- mixed hyperplastic/adenomatous polyp
- serrated adenoma

#### Sessile Serrated Polyps

- Differences in morphology substantiated by differences in behavior and molecular features
  - Recognition based on molecular data that most of these represent a distinct neoplastic pathway
- (Gradual) reorganization of nomenclature to account for this

#### Polyp Types: Now

- Adenomatous
  - Tubular adenoma
  - Villous adenoma

#### Polyp Types: Now


- Adenomatous
  - Tubular adenoma
  - Villous adenoma


- Serrated
  - Hyperplastic
  - Sessile serrated adenoma/polyp
  - Serrated adenoma (traditional)


#### Adenomatous Polyps

Traditionally, the polyp type that we worry about

- Marked increase in frequency with increasing age
- Neoplastic (chromosomal instability) with malignant potential
- Villous (if mostly growing out) or tubular (if mostly growing in)







#### Serrated Polyps

Hyperplastic polyp

 Sessile serrated adenoma / sessile serrated polyp

 Serrated adenoma / traditional serrated adenoma


#### Hyperplastic Polyps (HPs)


- Most common serrated subtype (70-95%)
- Predominantly left-sided
- Usually small (< 5 mm)</li>

- Benign
  - May contribute to serrated polyposis syndrome

#### HP Appearance

- Straight, simple, symmetric crypts
  - No branching
- Wider and more serrated at the top
- Bland cytology, i.e., individual cells look basically normal
- Several different subtypes
  - No clear clinical difference between subtypes





# Sessile Serrated Adenoma / Sessile Serrated Polyp

- Relatively new term (2003)
  - Concept is somewhat older
  - Slow and somewhat uneasy adoption into general pathology practice
- Malignant potential

- Nomenclature: 'adenoma' vs 'polyp'
  - Use of both terms: 'sessile serrated adenoma/polyp'

#### SSP Appearance

- Serrated, mucin-rich appearance
  - May have mucin coating the surface
- Distorted architecture
  - Branching and dilation, 'boot-like' shape at base
- Increased maturation at base
- Increased proliferation
- May have increased cellular atypia (low- or highgrade dysplasia)
- May have areas that look like HP





#### Sessile Serrated Polyp

- How many 'boot-like' crypts?
  - WHO: 3
  - Consensus statement: 1

## Serrated Adenoma / Traditional Serrated Adenoma


- Least common type
- Not well defined
  - Studies probably contaminated with other polyp types

Malignant potential

#### TSA Apperance

- Stellate/serrated appearance
  - Decreased mucin production
- Variably dysplastic epithelium (low, high)





#### Unclassifiable Serrated Lesions


- Reasons you may get this diagnosis:
  - Overlapping histologic features
  - Technical problems with specimen or processing

#### Conventional Adenoma with Serrated Features

- Usually occur in patients with other serrated lesions
- Substantial proportion share molecular features with serrated polyps

# Serrated Polyp Types: Review

- HP prototype
  - Common, distal
  - Small
  - Benign
- SSP branching crypts
  - Common, proximal
  - Large
  - Malignant potential
- SA decreased mucin
  - Rare, proximal
  - Large
  - Malignant potential



#### **Epidemiology of Serrated Lesions**

Increase with increasing age

- Location:
  - More numerous in distal colon
  - More significant in proximal colon

#### Risk Factors for Serrated Lesions

- Distal (relatively less important, clinically)
  - Increased risk: cigarette smoking
  - Decreased risk: folate, exercise
  - Unclear: EtOH, fiber, NSAID, family CRC history, BMI

- Proximal (less data)
  - Increased risk: cigarette smoking

#### Molecular Features of Serrated Lesions

- Molecular Pathways of Carcinogenesis
  - Chromosomal instability (traditional, most adenomas)
  - CpG island methylator phenotype (CIMP)
  - Mismatch repair defects (MSI)
- SSP progression involves several of these

# MAPK Pathway Alteration


- BRAF mutations as early event
  - ~50-70% of serrated polyps

KRAS mutations less common

#### **CIMP**

- CIMP-high (methylation of an extensive set of genes)
  - Possible epigenetic silencing of MLH1 → MSI

- Present in some HPs, most SSPs
  - SAs more heterogeneous; possibly not a pure group




## Proposed Serrated Lesion Progression

SSP → dysplasia → carcinoma

- Although HPs share some molecular features with SSP, no evidence that they're premalignant
  - CIMP cancer risk increases progressively towards the proximal colon; HPs most common in the distal colon

## SSP → CA

<u>Histology</u>	Mean Age
SSP	61
SSP with low-grade dysplasia	66
SSP with high-grade dysplasia	72
SSP with carcinoma	76



# Serrated Polyposis Syndrome / Hyperplastic Polyposis Syndrome

- Predisposition to serrated polyps
- Relatively younger age of onset
- Family history of serrated polyps or colon cancer
  - Many cases are sporadic

#### **SPS: Definition**

- 1) At least 5 serrated polyps proximal to the sigmoid colon, with at least 2 > 10mm, or
- Any serrated polyps proximal to the sigmoid colon, in someone with a 1<sup>st</sup> degree relative with SPS, or
- 3) More than 20 serrated polyps, of any size, in any site in the colon

#### Fundamentally arbitrary definition

# SPS: Significance

- Increased risk of colon cancer
  - Uncertain degree
- If undergoing resection for carcinoma, also resect segments with large polyps
- Annual colonoscopy with removal of proximal polyps
- Screening for 1<sup>st</sup>-degree relatives starting at age 40
- No obvious risk of extracolonic malignancy

#### **Problems With Serrated Lesions**

- Diagnostic
  - Recognition of serrated lesion
  - HP versus Everything Else
  - Use of appropriate nomenclature

- Management
  - Diagnostic variability
  - Guidelines?

## Diagnostic Problems

- 1. Lack of clear nomenclature; inconsistent application of established nomenclature
  - What is it?

- 2. Lack of specific criteria
  - How do we know what it is?

- 3. Pathologist disagreement
  - Knowledge of nomenclature/criteria
- Pathologists may just disagree anyway

#### 1. Nomenclature

- Should be less of a problem, as concept of HPs / SSPs / TSAs is fairly well-established by now
  - Education

- Can't tell / want to play it safe
  - May be related to lack of clear diagnostic criteria
  - Sign-out as 'serrated polyp' or 'serrated lesion'
    - Because some are benign, some have malignant potential: not really a useful diagnosis

# 2. Diagnostic Criteria

#### Good news:

Some guidelines emerging

#### Bad news:

- Guidelines are recent; will probably take a while to catch on
- Some entities still not well defined (TSA)
- Data lacking for many of these decisions
  - Tendency to 'play it safe' and overdiagnose to ensure adequate follow-up

#### SSP vs HP

 Biggest problem (common polyps, with very different follow-up implications)

- Recommendation (as of 6/2012):
  - Even one distorted / 'boot-like' crypt is sufficient for SSP

# 3. Pathologist Disagreement

- Historically, a lot of interobserver variability
  - Improved when pathologists given clear rules

 Should improve as problems with nomenclature and diagnostic criteria are resolved

# Management Problems

- 1. Diagnostic variability/vagueness
  - Should (hopefully) continue to improve in the future


2. Lack of clear guidelines

3. Clinician familiarity with diagnosis

# Follow-Up: Guidelines

- Recent consensus statement (Rex et al, Am J Gastroenterol, 2012)
- Important considerations include:
  - Number
  - Location
  - Size
  - Histologic subtype
- Not a lot of evidence regarding natural history to guide follow-up guidelines

# Follow-Up: Basic Principles



6/17/2013

W. Sandy Twaddell, M.D.

62

# Follow-Up: HP

Histology	Size	Number	Location	Interval in years
HP	<10 mm	Any number <sup>b</sup>	Rectosigmoid	10°
HP	≤5mm	≤3	Proximal to sigmoid	10
HP	Any	≥4	Proximal to sigmoid	5
HP	>5mm	≥1	Proximal to sigmoid	5

Lesions diagnosed as HP larger than 1 cm should probably be considered as SSA/P

W. Sandy Twaddell, M.D.

# Follow-Up: SSP/SA

Histology	Size	Number	Location	Interval in years
SSA/P or TSA	<10mm	<3	Any	5
SSA/P or TSA	≥10 mm	1	Any	3
SSA/P or TSA	<10 mm	≥3	Any	3
SSA/P	≥10 mm	≥2	Any	1-3 <sup>d</sup>
SSA/P w/dysplasia	Any	Any		1–3e

6/17/2013

W. Sandy Twaddell, M.D.

64

From Rex et al, Am J Gastroenterol, 2012

# Take Away

 Accurate characterization of the number, size and location of lesions is dependent on the endoscopist.

- Accurate characterization of histology is dependent on the pathologist.
  - Can be quite variable
  - Advent of clear-cut guidelines may help in the future

#### What Your Report Says

(And what to do about it)

- Hyperplastic polyp: Benign
  - However, look for size/number/location: may indicate closer follow-up, worth commenting on
- SSA/SSP: Malignant potential, closer follow-up
- TSA: Malignant potential, closer follow-up
- 'Serrated lesion, unclassifiable':
  - Give the reason that it's unclassiiable
  - Presence/absence of dysplasia should be stated
  - No guidelines for follow-up
- Conventional adenoma with serrated features
  - No specific guidelines for follow-up

#### References

Glatz K et al. Am J Clin Pathol 2007. 127: 938-945

Kang GH. Arch Pathol Lab Med. 2011; 135: 698-703

Lane, N. Cancer Res. 1976, 36(7 part 2); 2669-72

Lash RH, Genta RM, Schuler CM. J Clin Pathol. 2010; 63:681-6

Limketkai BN et al. Gastro Endo, 2013; 77(3): 360-375

Longacre TA and Fenoglio-Presier CM. Am J Surg Pathol, 14(6), 524-67.

Pai RK et al. Am J Surg Pathol. 2010; 34(3):355-63

Rex DK *et al*, Am J Gastroenterol, 2012 (advance online publication)

Rosty C et al. J Gastroenterol 2013; 48: 287-302

Torlakovic et al. Am J Surg Pathol. 2003, 27:65-81



#### **THANK YOU!**

#### Prevention and Health Promotion Administration Center for Cancer Prevention and Control Cigarette Restitution Fund Program

For questions please contact Kelly Kesler, M.S., C.H.E.S. at (410) 767-0786

http://phpa.dhmh.maryland.gov